Chris Markoch

Chris Markoch

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

Virgin Galactic Is No Laughing Matter

Virgin Galactic shares got an artificial boost from a bullish call that turned out to be a joke. SPCE stock is still a speculative play.

Despite Legal Drama, Catalyst Pharmaceuticals Looks Oversold

Catalyst Pharmaceuticals stock has been on a wild ride since its drug got FDA approval -- and despite legal drama, it may be worth the risk.

Your First Instinct About Sorrento Therapeutics Is Probably Right

SRNE stock is down nearly 66% since August. The company is taking many swings at finding solutions for Covid-19, but it's runway simply isn't long enough.

Chesapeake Energy Must Be Praying for a Trump Victory

Chesapeake Energy stock is worthless coming out of bankruptcy and the company's narrow path to relevance will be complicated by a Biden win.

It’s Time to Place Your Bets On Landcadia Holdings

As virus cases surge, a range of outcomes are possible for the online gambling sector. That means now may not be the time to buy LCA stock.